A Crossover Study to Assess the Effects of FYU-981 on the QT/QTc Interval in Healthy Male and Female Volunteers
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs FYU-981 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Fuji Yakuhin
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 19 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.